Two molecular platforms, one respiratory diagnostic question
Respiratory virus testing remains a race against time in crowded wards, emergency departments, and pediatric units where clinicians need answers fast enough to shape isolation, antiviral use, and antibiotic decisions. In this comparative study from Ain Shams University Hospitals, investigators evaluated whether the open-PCR Allplex RV Master Assay could stand alongside the cartridge-based BioFire Respiratory Panel 2.1 plus for the detection of respiratory viruses in nasopharyngeal swabs.
The design was straightforward and clinically practical: 65 positive nasopharyngeal swabs collected from admitted patients with suspected respiratory tract infection were tested by both platforms. BioFire served as the comparator, and pathogen-specific agreement was assessed using positive percent agreement, negative percent agreement, Cohen’s kappa, and discordance rate. The question was not whether respiratory viruses mattered. They clearly do. The question was whether a slower, batch-based platform could perform well enough to serve as a reliable alternative when laboratories are balancing cost, throughput, and speed.
Agreement was strong for most viral targets
Across the 65 samples, both assays detected respiratory viruses in every specimen, but the pattern of positives differed in ways that matter for laboratory workflow and clinical interpretation. Human rhinovirus was the most frequently detected virus by both methods, appearing in 32 cases by BioFire and 36 cases by Allplex. Respiratory syncytial virus, adenovirus, influenza A, influenza B, parainfluenza virus, SARS-CoV-2, and metapneumovirus were also captured across the cohort, with some divergence in counts between the two assays.
Agreement was particularly strong for several targets. Cohen’s kappa reached 1.000 for parainfluenza virus and 0.877 for human rhinovirus, reflecting almost perfect agreement. Substantial agreement was also observed for SARS-CoV-2, adenovirus, influenza A, and RSV, with kappa values of 0.661, 0.765, 0.809, and 0.745, respectively. Influenza B showed moderate agreement at 0.488.
One result stands out. SARS-CoV-2 showed the lowest positive percent agreement at 75%.
That divergence is clinically important because respiratory panels are often used to settle isolation decisions early in admission, and even a modest mismatch can affect patient flow and infection control. The study also reported no discordant results for parainfluenza virus, while BioFire missed four rhinovirus cases that Allplex did not identify, and Allplex picked up additional positives for adenovirus, influenza A, influenza B, RSV, and metapneumovirus.
Platform design shaped speed, cost, and laboratory burden
The two systems are built for different operational realities. BioFire is a cartridge-based syndromic platform that delivers results in about 45 minutes and requires one cartridge per specimen. That makes it attractive in emergency settings where rapid turnaround can alter triage and isolation decisions almost immediately. Allplex, by contrast, requires nucleic acid extraction and batch processing, with a reported turnaround of roughly 3 to 4 hours. For high-volume laboratories, that extra time may be acceptable if it is offset by throughput and lower cost.
The economic gap was wide. Allplex was reported at about 16 dollars per test, while BioFire approached 120 dollars per test, a difference of roughly 7.5-fold. In settings where respiratory virus testing is frequent and budgets are constrained, that kind of cost separation can influence platform selection as much as analytic performance does. An assay that is both affordable and sufficiently concordant with the comparator can expand access to molecular diagnosis without forcing laboratories to sacrifice reliability.
The study also noted that Allplex identified more coinfections. In respiratory virology, that finding is not trivial. Coinfection can complicate symptom attribution, influence clinical expectations, and remind clinicians that a single positive result does not always tell the whole story in a patient with layered respiratory disease.
Discordant calls point to the edge cases laboratories must watch
Discordant samples clustered in a few viral targets. BioFire detected four rhinovirus cases missed by Allplex, while Allplex reported additional positives for adenovirus, influenza A, influenza B, RSV, and metapneumovirus that were negative on BioFire. No contamination signal was seen when discordant Allplex results were reviewed, and no evidence suggested adjacent-well contamination. Even so, the investigators did not use an independent confirmatory method to adjudicate discrepancies, leaving the true direction of disagreement unresolved.
That limitation narrows the strength of the comparison, because a head-to-head study is most persuasive when discordant results are verified with a third method. Without that step, differences between the assays can reflect analytical sensitivity, stochastic low-level detection, specimen variability, or occasional false positives and false negatives. The absence of confirmatory testing does not erase the pattern of agreement, but it does place a ceiling on how confidently the two platforms can be treated as interchangeable for every target.
The sample set itself also matters. All 65 specimens were already positive on BioFire for viral targets, so this was not a broad diagnostic accuracy study across all-comers. It was a targeted comparison inside a positive cohort, which is useful for agreement analysis but does not fully address real-world screening performance across the full spectrum of respiratory illness.
Why the comparison matters at the bedside
Respiratory virus diagnosis is rarely an abstract laboratory exercise. When viral etiology is identified early, clinicians can curb unnecessary antibiotics, reinforce infection control, and avoid prolonged diagnostic uncertainty. That is especially relevant in children, older adults, and immunocompromised patients, where respiratory infections drive major morbidity and mortality. The study’s findings support the view that open-PCR multiplex testing can serve as a credible alternative to cartridge-based syndromic testing when the laboratory needs broader batching and lower cost.
The biological rationale is familiar: multiplex nucleic acid amplification detects viral genomes directly, bypassing the delays of culture and the lag of serology. In practical terms, that means a hospital can move from suspicion to pathogen-directed action much earlier in the illness course. Even when two assays are not perfectly aligned on every target, a strong overall pattern of agreement can still be enough to guide day-to-day care, especially when the testing environment values throughput and affordability as much as speed.
The study leaves a few clinically relevant questions open. Discordant samples need adjudication with an independent reference method, and performance in a broader, unselected respiratory cohort would better reflect routine clinical use. Still, the central message is clear from the data presented here: Allplex RV Master Assay tracked closely with BioFire Respiratory Panel 2.1 plus for most viral targets, while offering lower per-test cost and a workflow suited to batch testing.